Insight Molecular Diagnostics Inc. Research and Development Expense
Insight Molecular Diagnostics Inc. (IMDX) reported Research and Development Expense of $4.49 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-10
- Insight Molecular Diagnostics Inc. research and development expense for the quarter ending 2026-06-30 was $4.49M, a 37.23% increase year-over-year.
- Insight Molecular Diagnostics Inc. research and development expense for the quarter ending 2026-03-31 was $4.95M, a 69.39% increase year-over-year.
- Insight Molecular Diagnostics Inc. research and development expense for the quarter ending 2025-12-31 was $5.83M, a 158.26% increase year-over-year.
- Insight Molecular Diagnostics Inc. research and development expense for the quarter ending 2025-09-30 was $3.88M, a 37.66% increase year-over-year.
- Insight Molecular Diagnostics Inc. research and development expense for fiscal 2025 was $15.90M, a 61.60% increase from fiscal 2024.
- Insight Molecular Diagnostics Inc. research and development expense for fiscal 2024 was $9.84M, a 5.86% increase from fiscal 2023.
- Insight Molecular Diagnostics Inc. research and development expense for fiscal 2023 was $9.29M, a 27.30% increase from fiscal 2022.
- Insight Molecular Diagnostics Inc. research and development expense for fiscal 2022 was $7.30M, a 45.00% increase from fiscal 2021.
| Period end | Research and Development Expense 2 month | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.49M 10-Q · filed 2026-08-10 | $9.44M 10-Q · filed 2026-08-10 | $15.27M derived: sum of 3 quarters · filed 2026-08-10 | $19.15M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2026-03-31 | $4.95M 10-Q · filed 2026-05-13 | $10.78M derived: sum of 2 quarters · filed 2026-05-13 | $14.66M derived: sum of 3 quarters · filed 2026-05-13 | $17.93M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-12-31 | $5.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $9.71M derived: sum of 2 quarters · filed 2026-03-26 | $12.98M derived: sum of 3 quarters · filed 2026-08-10 | $15.90M 10-K · filed 2026-03-26 | |||||
| 2025-09-30 | $3.88M 10-Q · filed 2025-11-10 | $7.15M derived: sum of 2 quarters · filed 2026-08-10 | $10.07M 10-Q · filed 2025-11-10 | $12.33M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-06-30 | $3.27M 10-Q · filed 2026-08-10 | $3.28M 10-Q · filed 2025-08-11 | $6.19M 10-Q · filed 2026-08-10 | $6.21M 10-Q · filed 2025-08-11 | $8.45M derived: sum of 3 quarters · filed 2026-08-10 | $11.27M derived: sum of 4 quarters · filed 2026-08-10 | |||
| 2025-03-31 | $2.92M 10-Q · filed 2026-05-13 | $5.18M derived: sum of 2 quarters · filed 2026-05-13 | $8.00M derived: sum of 3 quarters · filed 2026-05-13 | $10.45M derived: sum of 4 quarters · filed 2026-05-13 | |||||
| 2024-12-31 | $2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $5.07M derived: sum of 2 quarters · filed 2026-03-26 | $7.53M derived: sum of 3 quarters · filed 2026-03-26 | $9.84M 10-K · filed 2026-03-26 | |||||
| 2024-09-30 | $2.82M 10-Q · filed 2025-11-10 | $5.27M derived: sum of 2 quarters · filed 2025-11-10 | $7.58M 10-Q · filed 2025-11-10 | $10.13M derived: sum of 4 quarters · filed 2025-11-10 | |||||
| 2024-06-30 | $2.45M 10-Q · filed 2025-08-11 | $4.76M 10-Q · filed 2025-08-11 | $7.31M derived: sum of 3 quarters · filed 2025-08-11 | $9.50M derived: sum of 4 quarters · filed 2025-08-11 | |||||
| 2024-03-31 | $2.31M 10-Q · filed 2025-05-12 | $2.17M 10-Q · filed 2024-05-15 | $4.86M derived: sum of 2 quarters · filed 2025-05-12 | $7.04M derived: sum of 3 quarters · filed 2025-05-12 | $9.48M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $2.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $4.73M derived: sum of 2 quarters · filed 2025-03-24 | $7.17M derived: sum of 3 quarters · filed 2025-03-24 | $9.29M 10-K · filed 2025-03-24 | |||||
| 2023-09-30 | $2.19M 10-Q · filed 2024-11-12 | $4.62M derived: sum of 2 quarters · filed 2024-11-12 | $6.75M 10-Q · filed 2024-11-12 | $8.13M derived: sum of 4 quarters · filed 2024-11-12 | |||||
| 2023-06-30 | $2.44M 10-Q · filed 2024-08-08 | $4.56M 10-Q · filed 2024-08-08 | $5.94M derived: sum of 3 quarters · filed 2024-08-08 | $7.41M derived: sum of 4 quarters · filed 2024-08-08 | |||||
| 2023-03-31 | $2.13M 10-Q · filed 2024-05-15 | $3.50M derived: sum of 2 quarters · filed 2024-05-15 | $4.98M derived: sum of 3 quarters · filed 2024-05-15 | $7.42M derived: sum of 4 quarters · filed 2024-05-15 | |||||
| 2022-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $2.85M derived: sum of 2 quarters · filed 2024-04-16 | $5.29M derived: sum of 3 quarters · filed 2024-04-16 | $7.30M 10-K · filed 2024-04-16 | |||||
| 2022-09-30 | $1.47M 10-Q · filed 2023-11-09 | $4.42M 10-Q · filed 2022-11-10 | $3.92M derived: sum of 2 quarters · filed 2023-11-09 | $5.92M 10-Q · filed 2023-11-09 | $15.12M 10-Q · filed 2022-11-10 | $10.51M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $2.44M 10-Q · filed 2023-08-10 | $5.57M 10-Q · filed 2022-08-12 | $4.45M 10-Q · filed 2023-08-10 | $10.70M 10-Q · filed 2022-08-12 | $9.04M derived: sum of 3 quarters · filed 2023-08-10 | $12.18M derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | $2.01M 10-Q · filed 2023-05-15 | $5.13M 10-Q · filed 2022-05-12 | $6.60M derived: sum of 2 quarters · filed 2023-05-15 | $9.74M derived: sum of 3 quarters · filed 2023-05-15 | $12.28M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $4.59M 10-K · filed 2022-03-11 | $7.73M derived: sum of 2 quarters · filed 2022-11-10 | $10.27M derived: sum of 3 quarters · filed 2022-11-10 | $5.04M 10-K · filed 2023-04-12 | $13.63M 10-K · filed 2022-03-11 | ||||
| 2021-09-30 | $3.14M 10-Q · filed 2022-11-10 | $5.68M derived: sum of 2 quarters · filed 2022-11-10 | $9.04M 10-Q · filed 2022-11-10 | $10.84M derived: sum of 4 quarters · filed 2022-11-10 | |||||
| 2021-06-30 | $2.54M 10-Q · filed 2022-08-12 | $5.90M 10-Q · filed 2022-08-12 | $7.70M derived: sum of 3 quarters · filed 2022-08-12 | $10.31M derived: sum of 4 quarters · filed 2022-08-12 | |||||
| 2021-03-31 | $3.36M 10-Q · filed 2022-05-12 | $5.16M derived: sum of 2 quarters · filed 2022-05-12 | $7.78M derived: sum of 3 quarters · filed 2022-05-12 | $11.00M derived: sum of 4 quarters · filed 2022-05-12 | |||||
| 2021-02-23 | $125.00K 10-K · filed 2022-03-11 | ||||||||
| 2020-12-31 | $1.80M 10-K · filed 2022-03-11 | $4.42M derived: sum of 2 quarters · filed 2022-03-11 | $7.64M derived: sum of 3 quarters · filed 2022-03-11 | $9.80M 10-K · filed 2022-03-11 | |||||
| 2020-09-30 | $2.62M 10-K · filed 2022-03-11 | $5.84M derived: sum of 2 quarters · filed 2022-03-11 | $8.00M 10-Q · filed 2021-11-09 | $10.32M derived: sum of 4 quarters · filed 2022-03-11 | |||||
| 2020-06-30 | $3.23M 10-K · filed 2022-03-11 | $5.38M 10-Q · filed 2021-08-11 | $7.70M derived: sum of 3 quarters · filed 2022-03-11 | $9.33M derived: sum of 4 quarters · filed 2022-03-11 | |||||
| 2020-03-31 | $2.16M 10-K · filed 2022-03-11 | $4.48M derived: sum of 2 quarters · filed 2022-03-11 | $6.10M derived: sum of 3 quarters · filed 2022-03-11 | $7.61M derived: sum of 4 quarters · filed 2022-03-11 | |||||
| 2019-12-31 | $2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | $3.94M derived: sum of 2 quarters · filed 2021-03-19 | $5.45M derived: sum of 3 quarters · filed 2021-03-19 | $6.79M 10-K · filed 2021-03-19 | |||||
| 2019-09-30 | $1.63M 10-Q · filed 2020-11-12 | $3.13M derived: sum of 2 quarters · filed 2020-11-12 | $4.48M 10-Q · filed 2020-11-12 | $5.68M derived: sum of 4 quarters · filed 2020-11-12 | |||||
| 2019-06-30 | $1.51M 10-Q · filed 2020-07-29 | $2.85M 10-Q · filed 2020-07-29 | $4.05M derived: sum of 3 quarters · filed 2020-07-29 | $5.58M derived: sum of 4 quarters · filed 2020-07-29 | |||||
| 2019-03-31 | $1.34M 10-Q · filed 2020-05-12 | $2.55M derived: sum of 2 quarters · filed 2020-05-12 | $4.07M derived: sum of 3 quarters · filed 2020-05-12 | $6.40M derived: sum of 4 quarters · filed 2020-05-12 | |||||
| 2018-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $2.73M derived: sum of 2 quarters · filed 2020-03-26 | $5.05M derived: sum of 3 quarters · filed 2020-03-26 | $6.51M 10-K · filed 2020-03-26 | |||||
| 2018-09-30 | $1.53M 10-Q · filed 2019-11-14 | $3.85M derived: sum of 2 quarters · filed 2019-11-14 | $5.31M 10-Q · filed 2019-11-14 | $6.82M derived: sum of 4 quarters · filed 2019-11-14 | |||||
| 2018-06-30 | $2.32M 10-Q · filed 2019-08-14 | $3.78M 10-Q · filed 2019-08-14 | $5.29M derived: sum of 3 quarters · filed 2019-08-14 | $7.13M derived: sum of 4 quarters · filed 2019-08-14 | |||||
| 2018-03-31 | $1.46M 10-Q · filed 2019-05-14 | $2.97M derived: sum of 2 quarters · filed 2019-05-14 | $4.80M derived: sum of 3 quarters · filed 2019-05-14 | $6.80M derived: sum of 4 quarters · filed 2019-05-14 | |||||
| 2017-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $3.34M derived: sum of 2 quarters · filed 2019-04-01 | $5.34M derived: sum of 3 quarters · filed 2019-04-01 | $7.17M 10-K · filed 2019-04-01 | |||||
| 2017-09-30 | $1.84M 10-Q · filed 2018-11-13 | $3.83M derived: sum of 2 quarters · filed 2018-11-13 | $5.67M 10-Q · filed 2018-11-13 | $7.10M derived: sum of 4 quarters · filed 2018-11-13 | |||||
| 2017-06-30 | $2.00M 10-Q · filed 2018-08-14 | $3.83M 10-Q · filed 2018-08-14 | $5.26M derived: sum of 3 quarters · filed 2018-08-14 | $6.63M derived: sum of 4 quarters · filed 2018-08-14 | |||||
| 2017-03-31 | $1.83M 10-Q · filed 2018-05-15 | $3.27M derived: sum of 2 quarters · filed 2018-05-15 | $4.63M derived: sum of 3 quarters · filed 2018-05-15 | $5.82M derived: sum of 4 quarters · filed 2018-05-15 | |||||
| 2016-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $2.79M derived: sum of 2 quarters · filed 2018-04-02 | $3.99M derived: sum of 3 quarters · filed 2018-04-02 | $5.68M 10-K · filed 2018-04-02 | |||||
| 2016-09-30 | $1.36M 10-Q · filed 2017-11-14 | $2.56M derived: sum of 2 quarters · filed 2017-11-14 | $4.25M 10-Q · filed 2017-11-14 | $5.68M derived: sum of 4 quarters · filed 2018-04-02 | |||||
| 2016-06-30 | $1.20M 10-Q · filed 2017-08-14 | $2.88M 10-Q · filed 2017-08-14 | $4.31M derived: sum of 3 quarters · filed 2018-04-02 | $5.41M derived: sum of 4 quarters · filed 2018-04-02 | |||||
| 2016-03-31 | $1.69M 10-Q · filed 2017-04-28 | $3.12M derived: sum of 2 quarters · filed 2018-04-02 | $4.21M derived: sum of 3 quarters · filed 2018-04-02 | $5.10M derived: sum of 4 quarters · filed 2018-04-02 | |||||
| 2015-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $2.52M derived: sum of 2 quarters · filed 2018-04-02 | $3.41M derived: sum of 3 quarters · filed 2018-04-02 | $4.53M 10-K · filed 2018-04-02 | |||||
| 2015-09-30 | $1.09M 10-Q · filed 2016-11-10 | $1.98M derived: sum of 2 quarters · filed 2016-11-10 | $3.10M 10-Q · filed 2016-11-10 | ||||||
| 2015-06-30 | $886.00K 10-Q · filed 2016-08-11 | $2.00M 10-Q · filed 2016-08-11 | |||||||
| 2015-03-31 | $1.12M 10-Q · filed 2016-05-16 | ||||||||
| 2014-12-31 | $3.96M 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |